









Markets
/
Stocks
/
nasdaq-eypt
/

EyePoint Pharmaceuticals Inc

EYPT



View Detailed Chart

18.260USD

-0.120-0.65%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

1.27BMarket Cap

LossP/E TTM



EyePoint Pharmaceuticals Inc

18.260

-0.120-0.65%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-0.65%

5 Days

+9.60%

1 Month

+26.81%

6 Months

+98.91%

Year to Date

+145.10%

1 Year

+149.11%

View Detailed Chart

TradingKey Stock Score of EyePoint Pharmaceuticals Inc

Currency: USD Updated: 2025-12-24

Key Insights

EyePoint Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 55/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.55.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

EyePoint Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

55 / 158

Overall Ranking

132 / 4562

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

32.545

Target Price

+82.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

EyePoint Pharmaceuticals Inc Highlights

StrengthsRisks

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

Growing

The company is in a growing phase, with the latest annual income totaling USD 43.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 43.27M.

Undervalued

The company’s latest PE is -6.08, at a low 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 257.34K shares of this stock.